Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial — Matias Trillini (2023) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial
Shared by
Giuseppe Remuzzi
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial
Article
2023
en
Authors
+13 more
MT
Matias Trillini
AC
Anna Caroli
NP
Norberto Perico
Abstract
1 min read
Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL), NCT03541447.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2022
Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy
Piero Ruggenenti
,
Annalisa Perna
,
Anna Caroli
,
Norberto Perico
,
Mattias Trillini
,
Antonio Pisani
,
Letìzia Spinelli
,
Giuseppe Remuzzi
Article
2025
The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care
Monica Cortinovis
,
Norberto Perico
,
Giuseppe Remuzzi
Article
2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Norberto Perico
,
Piero Ruggenenti
,
Annalisa Perna
,
Anna Caroli
,
Matias Trillini
,
Sandro Sironi
,
Antonio Pisani
,
Eleonora Riccio
,
Massimo Imbriaco
,
Mauro Dugo
,
Giovanni Morana
,
Antonio Granata
,
Michele Figuera
,
Flavio Gaspari
,
Fabiola Carrara
,
Nadia Rubis
,
Alessandro Villa
,
Sara Gamba
,
Silvia Prandini
,
Monica Cortinovis
,
Andrea Remuzzi
,
Giuseppe Remuzzi
Article
2016
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4
Piero Ruggenenti
,
Giorgio Gentile
,
Norberto Perico
,
Annalisa Perna
,
Luca Barcella
,
Matias Trillini
,
Monica Cortinovis
,
Claudia Patricia Ferrer Siles
,
Jorge Arturo Reyes Loaeza
,
M Aparicio
,
Giorgio Fasolini
,
Flavio Gaspari
,
Davide Martinetti
,
Fabiola Carrara
,
Nadia Rubis
,
Silvia Prandini
,
Anna Caroli
,
Kanishka Sharma
,
Luca Antiga
,
Andrea Remuzzi
,
Giuseppe Remuzzi
Dataset
Faculty Opinions recommendation of Tolvaptan in patients with autosomal dominant polycystic kidney disease.
Giuseppe Remuzzi
,
Arrigo Schieppati
Discussion(0)
No comments yet. Be the first to comment.